Cancer Epidemiology
Volume 34, Issue 5 , Pages 574-579 , October 2010

A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer

  • J. Hammarsten

      Affiliations

    • Department of Surgery, Section of Urology, Central Hospital, Karlstad, Sweden
    • Corresponding Author InformationCorresponding author at: Leopardgatan 3, S-432 37 Varberg, Sweden. Tel.: +46 340 10614; fax: +46 340 10614.
    • ,
  • J.-E. Damber

      Affiliations

    • Institute of Surgical Science, Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden
    • ,
  • R. Peeker

      Affiliations

    • Institute of Surgical Science, Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden
    • ,
  • D. Mellström

      Affiliations

    • Centre of Bone Research at the Sahlgrenska Academy, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden
    • ,
  • B. Högstedt

      Affiliations

    • Department of Occupational Medicine, Central Hospital, Halmstad, Sweden

,Accepted 21 June 2010.

References 

  1. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res. 2003;35(11–12):694–704
  2. Hsing AW, Streamson C, Gao Y-T, Gentzschein E, Chang L, Deng J. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J. Natl. Cancer Inst. 2001;93:783–789
  3. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate. 2002;50:1–3
  4. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high stage and high grade clinical prostate cancer. Blood Press. 2004;13:47–55
  5. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41:2887–2895
  6. Nandeesha H, Koner BC, Dorairajan LN. Altered insulin sensitivity, insulin secretion and lipid profile in non-diabetic prostate carcinoma. Acta Physiol Hung. 2008;95(1):97–105
  7. Ma J, Li H, Giovannucci E, Mucci L, Qui W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology. 2008;9:1039–1047
  8. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer. 2005;103:76–84
  9. Stattin P, Södeberg S, Hallmans G, Bylund A, Kaaks R, Stenman U-H, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001;86:1341–1345
  10. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology. 2004;63:253–258
  11. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, et al. Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden. Int J Cancer. 2007;120:2678–2686
  12. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours, International Histological Classification of Tumours No. 22. Geneva: WHO; 1980;
  13. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl. 1992;4:129–138
  14. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology. 1991;179:49–53
  15. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991;145:984–987
  16. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194
  17. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome?. Obes Rev. 2002;3:303–308
  18. Barnard R. J Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr. 2007;86(Suppl.):889S–893S
  19. Hammarsten J. Benign prostatic hyperplasia and clinical prostate cancer—two new components of the metabolic syndrome. Curr Hypertens Rev. 2006;2:301–309
  20. Albanes D, Weinstein SJ, Wright ME, Männistö S, Limburg PG, Snyder K, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101:1272–1279
  21. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2008;72:1102–1105
  22. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur. J Endocrinol. 2003;149:601–608
  23. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–1044
  24. Haffner SM, Valdez RA, Mykkänen L, Stern MP, Katz MS. Decreased testosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 1994;43:599–603
  25. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88–97
  26. Fowke JH, Matthews CM, Buchowski MS, Signerorello LB, Chang SS, Cookson MS, et al. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American. Prostate Cancer and Prostatic Diseases. 2008;11:264–269
  27. Ohwaki K, Endo F, Muraishi O, Hiramatsu S, Yano E. Relationship between prostate-specific antigen and hematocrit: does hemodilution lead to a lower PSA concentrations in men with a higher body mass index?. Urology. 2010;75:648–653
  28. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–158
  29. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinaemia and Dyslipidaemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370(1–2):89–93
  30. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51(1):199–206
  31. Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168:599–604
  32. Qiang L, Shinichi K, Masako K, Hong Y, Toshimasa S, Masato K, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control. 2010;21:1025–1032
  33. Stocks T, Hergens M-P, Englund A, Ye W, Stattin P. Blood pressure, body size and prostate cancer in the Swedish Constuction Workers cohort. Int J Cancer. 2010, early view.
  34. Chan JM, Stampfer MJ, Giovannunucci E, et al. Plasma-insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science. 1998;279:563–566
  35. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman U-H, et al. Plasma insulin-like growth factor-1, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92:1910–1917
  36. Wolk A, Mantzoros CS, Andersson S-O, Bergström R, Signorello LB, Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998;90:911–915
  37. Cox ME, Gleave ME, Zakikhani M, Bell RB, Piura E, Vicers E, et al. Insulin receptor expression by human prostate cancers. Prostate. 2009;69:33–40
  38. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007;99:1793–1800

PII: S1877-7821(10)00120-7

doi: 10.1016/j.canep.2010.06.014

Cancer Epidemiology
Volume 34, Issue 5 , Pages 574-579 , October 2010

Article Tools

* Image Usage & Resolution